Actuarial survival for all 145 patients was 0.45^0.04 after 5 years, 0.35^0.04 after 10 years and 0.23^0.04 after 15 years. Regarding lymph node involvement, 10-year survival for N0 disease was 0.53^0.06, for N1 disease 0.21^0.05, and for N2 disease 0.06^0.06 (Fig.1) . A highly signi®cant difference was found between N0 and N1 disease (P 0:0001) and between N0 and N2 disease (P , 0:0001). The difference between N1 and N2 disease reached statistical signi®cance (P 0:047).
model showed only two signi®cant variables in relation to survival: nodal stage (P , 0:0001) and age of the patient (P 0:0007).
The relationship between long-term survival after sleeve lobectomy and lymph node involvement remains controversial. Those recent studies reporting 5-and 10-year survival rates are summarized in Table 1 . The 5-year survival rate in patients with N1 disease ranges from 29 to 46%, and in N2 disease from 0 to 33%. Mehran and colleagues also found a highly signi®cant difference between N0 and N2 disease, between N1 and N2 disease, but no difference between N0 and N1 disease [2] . However, in their most recent data presented at the EACTS meeting in Glasgow, September 1999 (abstract no. 196 presented by F. Tronc) a signi®cant difference was found between N0 and N1 disease.
Should a pneumonectomy be done in case of N1 disease? When analyzing the cause of death in our series, most of the patients with N1 or N2 disease died of distant metastases. So, in our opinion, N1 disease is no contraindication for sleeve resection but patients with N1 or N2 disease should be regarded as having systemic disease and adjuvant treatment should be considered. In our multivariate analysis the new stage classi®cation of 1997 was no independent factor in relation to survival, the most signi®cant factor being nodal stage.
Appendix A. Conference discussion Dr J. Hasse (Freiburg, Germany): As a question: you had quite a considerable proportion of patients in all categories who died from other reasons than progression of carcinoma. Were those mainly cardiovascular disease or other cancers? Could you comment on that?
Dr Van Schil: Most of the patients dying of other diseases died primarily of cardiovascular diseases, and the second cause was other malignancies outside the chest.
Mr A. Ritchie (Cambridge, UK): Could I ask that your results would be much clearer if you took the 10% or so of carcinoid patients out. This is because the crux of the paper is whether sleeve resection is a good tumor operation or not.
And can I ask you just then, on that basis, to comment on the survival of N0 stage patients who should effectively have a surgical cure of their tumor. Do you think in that group of patients this is a good cancer operation?
Dr Van Schil: Regarding histological type and long-term survival, we included the 13 patients with carcinoid tumor, as they are listed under malignant invasive epithelial tumors in the most recent World Health Organization classi®cation. Fifteen-year survival in this group was indeed 100%. But those were only 13 patients. In the 116 patients with squamous cell carcinoma, we had a very good survival in N0 disease and rather poor survival in N1 or N2 disease.
There is a group from Canada, Dr Deslauriers', who will present their updated results in another session, who ®nd a much better survival in N1 disease than we did. But they included many cases of sleeve resections for hilar N1 involvement, which was rather exceptional in our series. But in fact, besides the carcinoid tumors, the patients with squamous cell carcinoma, N0 disease, have a far better prognosis than, for example, N1, N2 disease or the patients with adenocarcinoma where we had a 5-year survival rate of only 22%. 
